来凯医药-B拟配售3600万股 净筹约5.775亿港元

Core Viewpoint - 来凯医药-B plans to place 36 million shares, representing approximately 8.1% of the enlarged share capital post-placement, at a price of HKD 16.30 per share, which is about a 9.5% discount to the closing price of HKD 18.01 on September 9 [1] Fundraising Details - The total expected fundraising amount is HKD 586.8 million, with net proceeds estimated at HKD 577.5 million [1] - Approximately 90% of the raised funds will be allocated to the research and development of clinical and pre-clinical pipeline projects, while the remaining 10% will be used for general and corporate purposes [1]